Eli Lilly and Co.'s second-quarter earnings surpassed Wall Street estimates as sales of its blockbuster weight-loss drugs soared. "Mounjaro, Zepbound and Verzenio led our strong financial ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s initial sales expectations. Zepbound sales reached $1.9 billion in ...

Discover the latest business news including rising gas prices, Zepbound shipments, At Home bankruptcy, and the Federal Reserve meeting.

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

Fortunately, Headrick had heard of Lilly’s direct-to-consumer online pharmacy ... Lilly declined to provide sales or growth data for LillyDirect. But Zepbound paid for by patients outside ...

Last summer, Lilly started selling vials of the 2.5 mg and 5 mg doses of Zepbound online through its LillyDirect platform. Patients either need a prescription from their doctor or can get one ...

Sales of Zepbound were $1.26 billion in the quarter, missing the $1.76 billion expected by analysts. "The primary culprit was an inventory hit to Mounjaro and Zepbound ... not weaker demand ...